Multicenter research into the quality of life of patients with advanced oropharyngeal carcinoma with long‑term survival associated with human papilloma virus

Spinato,Giacomo; Stellin,Marco; Azzarello,Giuseppe; Bonazza,Deborah; Zanconati,Fabrizio; Politi,Doriano; Cocuzza,Salvatore; Di Mauro,Paola; Ausoni,Simonetta; Tonoli,Giovanni; Costantini,Giulio; Maiolino,Luigi; Spinato,Roberto; Da Mosto,Maria Cristina; Baboci,Lorena; Del Mistro,Annarosa; Serra,Agostino; Tirelli,Giancarlo

doi:10.3892/ol.2017.6152

Multicenter research into the quality of life of patients with advanced oropharyngeal carcinoma with long‑term survival associated with human papilloma virus

Authors:
- Giacomo Spinato
- Marco Stellin
- Giuseppe Azzarello
- Deborah Bonazza
- Fabrizio Zanconati
- Doriano Politi
- Salvatore Cocuzza
- Paola Di Mauro
- Simonetta Ausoni
- Giovanni Tonoli
- Giulio Costantini
- Luigi Maiolino
- Roberto Spinato
- Maria Cristina Da Mosto
- Lorena Baboci
- Annarosa Del Mistro
- Agostino Serra
- Giancarlo Tirelli
View Affiliations

Affiliations: Ear, Nose and Throat Department, Rovigo Provincial Hospital, I‑45100 Rovigo, Italy, Department of Neurosciences, Ear, Nose and Throat Clinic and Regional Center for Head and Neck Cancer, University of Padua, Treviso Provincial Hospital, I‑35122 Padua, Italy, Medical Oncology Department, Mirano Hospital, I‑300035 Venice, Italy, Pathology Department, Cattinara Hospital, University of Trieste, I‑34149 Trieste, Italy, Provincial Ear, Nose and Throat Department of Venice, Mestre Hospital, I‑30174 Venice, Italy, Ear, Nose and Throat Department, University of Catania, I‑95125 Catania, Italy, Department of Biomedical Sciences, University of Padua, I‑35122 Padua, Italy, Psychology Department, University of Milano‑Bicocca, I‑20126 Milan, Italy, Veneto Institute of Oncology IOV‑IRCCS, Immunology and Molecular Oncology Unit, Padua, I‑35128 Padova, Italy, Ear, Nose and Throat Department, Cattinara Hospital, University of Trieste, I‑34149 Trieste, Italy
Published online on: May 10, 2017 https://doi.org/10.3892/ol.2017.6152
Pages: 185-193
Copyright: © Spinato et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The treatment of advanced-stage oropharyngeal squamous cell carcinoma may utilize various modes, including combining surgery with chemoradiotherapy (CTRT), or primary CTRT followed by rescue surgery. In previous literature it has been revealed how patients treated with combined modes report a low quality of life (QoL) and severe consequences following surgery, radiotherapy and chemotherapy, in the short and in the long‑term. The decrease in the QoL of patients treated with high‑intensity multi‑modal strategies highlights the necessity of modifying treatments, particularly for young HPV‑positive patients, where an increased survival rate has already been reported. The modified treatment for HPV‑positive tumors in the tonsils and at the base of the tongue is based on the deintensification of therapies aiming to reduce toxicity and thereby improve QoL in the long term, whilst still maintaining therapeutic effectiveness. The aim of the present study was to evaluate the QoL in patients with a long‑term survival, who were treated with combined therapy for squamous cell tumors in the tonsils and at the base of the tongue, and to compare the results observed in HPV‑positive and HPV‑negative patients. According to statistical analysis, differences in the general QoL and in the single scales of the European Organization for the Research and Treatment of Cancer questionnaires were not correlated with the type of therapy selected for the particular patient. QoL considered the presence of HPV, the type of treatment, the subregion of the tonsils vs. the base of the tongue and the disease stage at the time of diagnosis, and was determined to be non‑influential with regard to these specific variables.

View Figures

View References

1	Shah JP, Patel SG and Singh B: Jatin Shah's Head and Neck Surgery and Oncology. 4th. Elsevier; Philadelphia, PA: 2012
2	Ragin CC and Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. Int J Cancer. 121:1813–1820. 2007. View Article : Google Scholar : PubMed/NCBI
3	Bussu F, Sali M, Gallus R, Petrone G, Zannoni GF, Autorino R, Dinapoli N, Santangelo R, Vellone VG, Graziani C, et al: Human Papillomavirus (HPV) infection in squamous cell carcinomas arising from the oropharynx: Detection of HPV DNA and p16 immunohistochemistry as diagnostic and prognostic indicators-a pilot study. Int J Radiation Oncol Biol Phys. 89:1115–1120. 2014. View Article : Google Scholar
4	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)Head and Neck Cancers. Version 1.2015. National Comprehensive Cancer Network, Inc.; 2015
5	Boscolo-Rizzo P, Tirelli G, Mantovani M, Baggio V, Lupato V, Spinato G, Gava A and Da Mosto MC: Non-endemic locoregionally advanced nasopharyngeal carcinoma: Long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice. Eur Arch Otorhinolaryngol. 272:3491–3498. 2015. View Article : Google Scholar : PubMed/NCBI
6	Pourel N, Peiffert D, Lartigau E, Desandes E, Luporsi E and Conroy T: Quality of life in long-term survivors of oropharynx carcinoma. Int J Radiat Oncol Biol Phys. 54:742–51. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ausoni S, Boscolo-Rizzo P, Singh B, da Mosto MC, Spinato G, Tirelli G, Spinato R and Azzarello G: Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: Current options and emerging perspectives. Cancer Metastasis Rev. 35:413–426. 2016. View Article : Google Scholar : PubMed/NCBI
8	Rizzo P Boscolo, Rampazzo E, Perisinotto E, Piano MA, Giungo S, Baboci L, Spinato G, Spinato R, Tirelli G, da Mosto MC, et al: Telomere shortening in mucosa surrounding the tumor: Biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma. Oral Oncol. 51:500–507. 2015. View Article : Google Scholar : PubMed/NCBI
9	Elrefaey S, Massaro MA, Chiocca S, Chiesa F and Ansarin M: HPV in oropharyngeal cancer: The basics to know in clinical practice. Acta Otorhinolaryngol Ital. 34:299–309. 2014.PubMed/NCBI
10	Funk GF, Karnell LH and Christensen AJ: Long term health-related quality of life in survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg. 138:123–133. 2012. View Article : Google Scholar : PubMed/NCBI
11	Serra A, Caltabiano R, Scalia G, Palmucci S, Di Mauro P and Cocuzza S: Papillary squamous cell carcinoma of the palatine tonsil: A rare cancer of the head and neck. Acta Otorhinolaryngologica Italica. 37:1–5. 2017.PubMed/NCBI
12	Maxwell JH, Mehta V, Wang H, Cunningham D, Duvvuri U, Kim S, Johnson JT and Ferris RL: Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality. Laryngoscope. 124:1592–1597. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wan Leung S, Lee TF, Chien CY, Chao PJ, Tsai WL and Fang FM: Health related Quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QOL-H&N35 questionnaires. BMC Cancer. 11:1282011. View Article : Google Scholar : PubMed/NCBI
14	QoLQuestionnaire-Core 30 (QLQ-C30), EORTC-ITA. http://groups.eortc.be/qol/why-do-we-need-modulesMarch 3–2015
15	QoL Questionnaire-Head and Neck 35 (QLQ-H&N35), EORTC-ITA. http://groups.eortc.be/qol/why-do-we-need-modulesMarch 3–2015
16	Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D and Bottomley A; On behalf of the EORTC Quality of Life Group, : The EORTC QLQ-C30 Scoring Manual. 3rd. European Organization for Research and Treatment of Cancer; Brussels: 2001
17	Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, De Haes JC, et al: The European Organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85:365–376. 1993. View Article : Google Scholar : PubMed/NCBI
18	Baboci L, Holzinger D, Rizzo P Boscolo, Tirelli G, Spinato R, Lupato V, Fuson R, Schmitt M, Michel A, Halec G, et al: Low prevalence of HPV-driven head and neck squamous cell carcinoma in North-East Italy. Papillomavirus Research. 2:133–140. 2016. View Article : Google Scholar
19	Schmitt M, Dondog B, Waterboer T and Pawlita M: Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol. 46:1050–1059. 2008. View Article : Google Scholar : PubMed/NCBI
20	Del Mistro A, Bonaldi L, Bertorelle R, Minucci D, Franzetti M, Cattelan A, Bonoldi E, Sposetti R, Torrisi A and Bianchi L Chieco: Genital human papillomavirus types in immunocompetent and immunodepressed women in northeast Italy: Prevalence and cytomorphological correlations. J Low Genit Tract Dis. 5:12–20. 2001. View Article : Google Scholar : PubMed/NCBI
21	Carson F and Hladik C: Histotechnology: A Self Instructional Text. 3rd. American Society for Clinical Pathology Press; Hong Kong: 2009
22	Roche PC and Hsi ED: Immunohistochemistry-Principles and AdvancesManual of Clinical Laboratory Immunology. Rose NR: 6th. ASM Press; Washington DC: 2002
23	Field A, Miles J and Field Z: Discovering Statistics Using R. SAGE Publications; London: 2012
24	Ruxton GD: The unequal variance t-test is an underused alternative to Student's t-test and the Mann-Whitney U test. Behav Ecol. 17:688–690. 2006. View Article : Google Scholar
25	Hinni ML and Lott DG: Contemporary Transoral Surgery for Primary Head and Neck Cancer. Plural Publishing; San Diego, CA: 2014
26	O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, et al: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 31:543–550. 2013. View Article : Google Scholar : PubMed/NCBI
27	Mendenhall WM, Amdur RJ, Morris CG, Kirwan JM and Li JG: Intensity-modulated radiotherapy for oropharyngeal squamous cell carcinoma. Laryngoscope. 120:2218–2222. 2010. View Article : Google Scholar : PubMed/NCBI
28	Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR and Ang KK: Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00–22). Int J Radiat Oncol Biol Phys. 76:1333–1338. 2010. View Article : Google Scholar : PubMed/NCBI
29	Yong JH, Beca J, O'Sullivan B, Huang SH, McGowan T, Warde P and Hoch JS: Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer. Clin Oncol (R Coll Radiol). 24:532–538. 2012. View Article : Google Scholar : PubMed/NCBI
30	Kurzweg T, Möckelmann N, Laban S and Knecht R: Current treatment options for recurrent or metastatic head neck cancer: A post-ASCO 2011 update and review of last year's literature. Eur Arch Otorhinolaryngol. 269:2157–2167. 2012. View Article : Google Scholar : PubMed/NCBI
31	Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA and Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC), : Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 23:1016–1022. 2012. View Article : Google Scholar : PubMed/NCBI
32	Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, O'Sullivan B, Waldron J, Cummings B, Kim J, et al: Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 27:6213–6221. 2009. View Article : Google Scholar : PubMed/NCBI
33	Baboci L, Boscolo-Rizzo P, Holzinger D, Bertorelle R, Biasini L, Michel A, Schmitt M, Spinato G, Bussani R, Alemany L, et al: Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virol J. 10:3342013. View Article : Google Scholar : PubMed/NCBI
34	D'Souza G and Dempsey A: The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 53 Suppl 1:S5–S11. 2011. View Article : Google Scholar : PubMed/NCBI
35	Fallai C, Perrone F, Licitra L, Pilotti S, Locati L, Bossi P, Orlandi E, Palazzi M and Olmi P: Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: Prognostic role of TP53 and HPV status. Int J Radiat Oncol Biol Phys. 75:1053–1059. 2009. View Article : Google Scholar : PubMed/NCBI
36	Franchin G, Minatel E, Gobitti C, Talamini R, Vaccher E, Sartor G, Politi D, Trovò MG and Barzan L: Radiotherapy for patients with early-stage glottic carcinoma: Univariate and multivariate analyses in a group of consecutive, unselected patients. Cancer. 98:765–772. 2003. View Article : Google Scholar : PubMed/NCBI
37	Da Mosto MC, Lupato V, Romeo S, Spinato G, Addonisio G, Baggio V, Gava A and Boscolo-Rizzo P: Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease? Ann Surg Oncol. 20:250–256. 2013. View Article : Google Scholar : PubMed/NCBI
38	Pignon JP, Bourhis J, Domenge C and Designé L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 355:949–955. 2000. View Article : Google Scholar : PubMed/NCBI
39	Sharma A, Méndez E, Yueh B, Lohavanichbutr P, Houck J, Doody DR, Futran ND, Upton MP, Schwartz SM and Chen C: Human papillomavirus-positive oral cavity and oropharyngeal cancer patients do not have better quality-of-life trajectories. Otolaryngol Head Neck Surg. 146:739–745. 2012. View Article : Google Scholar : PubMed/NCBI